RT Journal Article
SR Electronic
T1 The Association between Multimorbidity and Out-of-Pocket Expenditures for Prescription Medicines among Adults in Denmark: A Population-Based Register Study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.11.21.23298458
DO 10.1101/2023.11.21.23298458
A1 Larkin, James
A1 Smith, Susan M.
A1 Christensen, Line Due
A1 Voss, Thomas Schmidt
A1 Vestergaard, Claus Høstrup
A1 Paust, Amanda
A1 Prior, Anders
YR 2023
UL http://medrxiv.org/content/early/2023/11/22/2023.11.21.23298458.abstract
AB Background Multimorbidity, defined as two or more chronic conditions in an individual, is increasing in prevalence and is associated with polypharmacy. Polypharmacy can lead to increased out-of-pocket payments for prescription medicines. This, in turn, can be associated with cost-related non-adherence and impoverishment. Healthcare in Denmark is mostly free at the point-of-use; prescription medicines are one of the only exceptions.Objective To examine the association between multimorbidity and annual out-of-pocket prescription medicine expenditure for adults in Denmark.Methods A population-based register study was conducted. The study population included all adults residing in Denmark in 2020. Frequencies and descriptive statistics were used and regression analyses were conducted to assess the association between multimorbidity and annual out-of-pocket prescription medicine expenditure, while controlling for demographic and socioeconomic covariates.Results Overall, 1,212,033 (24.2%) individuals had multimorbidity. Individuals with five or more conditions spent, on average, €320 in out-of-pocket prescription medicines expenditure compared to €187 for those with two conditions and €44 for those with no conditions. Amongst those with any out-of-pocket prescription medicine expenditure, having multimorbidity was associated with 2-4 times greater out-of-pocket prescription medicine expenditure than those with zero conditions. Amongst those in the quantile with the highest expenditure, those with five or more conditions spent €408 more than those with no conditions, and those with two conditions spent €185 more than those with no conditions.Conclusions For adults in Denmark, multimorbidity was associated with significantly higher out-of-pocket prescription medicine expenditure, even after controlling for demographic and socioeconomic covariates. This is similar to patterns in other countries and likely affects those with lowest income the most, given the known socioeconomic patterning of multimorbidity and raises concerns about cost related non-adherence. Potential protective mechanisms could include subsidies for certain vulnerable patient groups (e.g. those with severe mental illness) and low-income groups.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo direct funding was received for this study. AP and CHV were supported by the General Practice Research Foundation of Central Denmark Region. The doctoral studies of JL were funded by the Health Research Board of Ireland (funding reference CDA-2018-003).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval and informed consent were not needed as the study was based on de-identified register data encrypted by and stored with Statistics Denmark. The study was approved by the Scientific Board of Statistics Denmark and the Danish Data Protection Agency.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe dataset is available at Statistics Denmark (https://www. dst.dk/en) and the Danish Health Data Authority (https://sundhedsdatastyrelsen.dk/da/english/). Data access is restricted to authorized research institutions by Danish law.